Mary Ann Liebert, Inc., publishers and Genetic Engineering & Biotechnology News (GEN) have announced the launch of GEN Biotechnology, a groundbreaking multidisciplinary peer-reviewed journal for exceptional research breakthroughs, news, and analysis directly impacting biotech.
GEN Biotechnology will provide a dynamic new peer-reviewed complement to GEN, the biotechnology industry’s flagship news publication that has covered the biotech industry for the past 40 years. GEN Biotechnology will complement the many preeminent biomedical journals in the Mary Ann Liebert, Inc. portfolio, including Human Gene Therapy, The CRISPR Journal, and Tissue Engineering.
The biotech industry is booming. New companies are being funded and going public on a weekly basis, and talented students and postdocs from leading research labs are increasingly moving to industry rather than staying in academia. Innovation continues to spark new therapeutic strategies and platforms. GEN Biotechnology will uniquely bring together both traditional academic audiences and executives and researchers from across the industry through exciting original research articles and reports, comprehensive review articles, news and analysis, interviews, and commentaries.
GEN Biotechnology will publish major advances across all aspects of basic and translational biotechnology research, including drug discovery, cell and gene therapy, immunotherapy, genome editing and writing, infectious diseases, artificial intelligence, agricultural biotechnology, bioengineering, neuroscience, cancer research, molecular diagnostics, the microbiome, and precision medicine. Each issue will also feature a critical mix of news/analysis stories and commentaries from key opinion leaders across the biotech industry.
GEN Biotechnology has begun to assemble a talented, diverse editorial board with expertise spanning all areas of editorial interest. A search for the chief editor is also underway. The Journal will shortly announce its initial call for research papers, with plans to publish a preview issue in 2021 and the inaugural issue in early 2022.
Click here to read the original press release.
